Elusys Therapeutics has published data from five clinical trials of ANTHIM, which was used to support the marketing approval by the U.S. Food and Drug Administration.
Read More »
MERCK: FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
CELGENE CORPORATION: Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO
ASTRAZENECA PHARMACEUTICALS LP: Lynparza in combination with abiraterone delayed disease progression in metastatic castration-resistant prostate cancer
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACIST: Joint Commission Eyes Overrides of Dispensing Cabinets
Sunovion’s new drug application for Latuda earns FDA review